You are here
Session on Haematologic Toxicities: anemia therapies and EORTC recommendations
By Pere Gascón, recorded at TAO (Transatlantic Oncology meeting), Nov 20-21, 2014, Paris
Pere Gascón speaks about the EORTC guidelines for the use of erythropoietic proteins in anemic patients with cancer. He reviews the 2011 position of the EORTC Working Party in comparison to the 2006 and 2007 EORTC guideline updates as well as the ASCO/ASH, NCCN and ESMO guidelines. The major goals of erythropoiesis-stimulating agents (ESA) are the prevention of transfusions and the improvement of quality of life. According to the 2011 position of the EORTC Working Party, ESA therapy decreases transfusion needs, ensures better maintenance of Hb levels than intermittent transfusions, improves quality of life in patients with chemotherapy-induced anemia and should be used within the guidelines. Prophylactic use of erythropoietic proteins to prevent anemia in patients who undergo chemo- and/or radiotherapy and have normal Hb values at the start of treatment is not recommended.
Pere Gascón, Hospital Clinic de Barcelona, Spain